Literature DB >> 2137485

Anti-CD3 antibody induces unresponsiveness to IL-2 in Th1 clones but not in Th2 clones.

M E Williams1, A H Lichtman, A K Abbas.   

Abstract

Culture of murine T cells with immobilized (platebound) anti-CD3 antibody results in autocrine growth factor secretion in both Th1 (IL-2 producing) and Th2 (IL-4 producing) cells. Using a panel of murine T cell clones, we demonstrate that the IL-2-induced proliferation of Th1 clones is dramatically inhibited by immobilized anti-CD3 antibody, whereas that of Th2 clones is not. This unresponsiveness of Th1 clones to IL-2 is not due to decreases in IL-2R expression. Supernatants from Th1 or Th2 cell cultures fail to alter the effects of anti-CD3 on the two types of clones, suggesting that unresponsiveness induced in Th1 clones or the lack thereof in Th2 clones is not mediated by a stable cytokine(s). Accessory cells enhance the proliferation of Th1 cells exposed to low concentrations of anti-CD3, but the unresponsiveness induced by high concentrations of anti-CD3 is not prevented by accessory cells. Finally, soluble anti-CD4 antibody prevents the induction of the unresponsive state even at high concentrations of anti-CD3. These experiments demonstrate that two subsets of cloned CD4+ T cells differ in their responses to anti-CD3, and that CD4 molecules may play a critical role in regulating the outcome of receptor-mediated stimulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137485

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  Xu Zhang; Raymond Hupperts; Marc De Baets
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 2.  Induction of Th2 cell tolerance to a soluble antigen by blockade of the LFA-1-dependent pathway prevents allergic inflammation.

Authors:  I Iwamoto; A Nakao
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

3.  Induction of T-cell activation or anergy determined by the combination of intensity and duration of T-cell receptor stimulation, and sequential induction in an individual cell.

Authors:  Tomohiro Yamamoto; Makoto Hattori; Tadashi Yoshida
Journal:  Immunology       Date:  2007-03-22       Impact factor: 7.397

4.  Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro.

Authors:  H M Diepolder; M C Jung; E Wierenga; R M Hoffmann; R Zachoval; T J Gerlach; S Scholz; G Heavner; G Riethmüller; G R Pape
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Differential requirements for induction of total immunoglobulin and physiological rheumatoid factor production by human peripheral blood B cells.

Authors:  W J Van Esch; C C Reparon-Schuijt; E W Levarht; C Van Kooten; F C Breedveld; C L Verweij
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

6.  Induction of abortive and productive proliferation in resting human T lymphocytes via CD3 and CD28.

Authors:  Y Müller; H Wolf; E Wierenga; G Jung
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

7.  Role of interleukin-2 in superantigen-induced T-cell anergy.

Authors:  W D Cornwell; T J Rogers
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

8.  cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells.

Authors:  T J Novak; E V Rothenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

9.  "Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype.

Authors:  T F Gajewski; D W Lancki; R Stack; F W Fitch
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

10.  Non-mitogenic anti-CD3F(ab')2 monoclonal antibody: a novel approach to control herpetic stromal keratitis.

Authors:  Pranita P Sarangi; Bumseok Kim; Barry T Rouse
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-08       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.